AKEBIA THERAPEUTICS INC (AKBA) Stock Fundamental Analysis
USA - NASDAQ:AKBA - US00972D1054 - Common Stock
1.67 USD
-0.09 (-5.11%)
1.66 USD
-0.01 (-0.6%)
Overall AKBA gets a fundamental rating of 3 out of 10. We evaluated AKBA against 531 industry peers in the Biotechnology industry. While AKBA is still in line with the averages on profitability rating, there are concerns on its financial health. AKBA has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year AKBA has reported negative net income.
AKBA had a negative operating cash flow in the past year.
In the past 5 years AKBA always reported negative net income.
AKBA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -10.56%, AKBA belongs to the top of the industry, outperforming 83.62% of the companies in the same industry.
AKBA has a Return On Equity (-124.84%) which is in line with its industry peers.
AKBA has a better Return On Invested Capital (1.39%) than 89.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.56% | ||
| ROE | -124.84% | ||
| ROIC | 1.39% |
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AKBA has a Operating Margin of 1.96%. This is amongst the best in the industry. AKBA outperforms 89.64% of its industry peers.
AKBA has a Gross Margin of 83.22%. This is amongst the best in the industry. AKBA outperforms 86.06% of its industry peers.
In the last couple of years the Gross Margin of AKBA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.96% | ||
| PM (TTM) | N/A | ||
| GM | 83.22% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
2. Health
2.1 Basic Checks
AKBA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for AKBA has been increased compared to 1 year ago.
AKBA has more shares outstanding than it did 5 years ago.
AKBA has a worse debt/assets ratio than last year.
2.2 Solvency
AKBA has an Altman-Z score of -4.86. This is a bad value and indicates that AKBA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.86, AKBA perfoms like the industry average, outperforming 40.30% of the companies in the same industry.
A Debt/Equity ratio of 6.07 is on the high side and indicates that AKBA has dependencies on debt financing.
The Debt to Equity ratio of AKBA (6.07) is worse than 83.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.86 |
ROIC/WACC0.18
WACC7.9%
2.3 Liquidity
A Current Ratio of 1.98 indicates that AKBA should not have too much problems paying its short term obligations.
AKBA has a Current ratio of 1.98. This is in the lower half of the industry: AKBA underperforms 75.71% of its industry peers.
AKBA has a Quick Ratio of 1.84. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AKBA (1.84) is worse than 76.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.84 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 69.57% over the past year.
Looking at the last year, AKBA shows a very negative growth in Revenue. The Revenue has decreased by -17.70% in the last year.
Measured over the past years, AKBA shows a very negative growth in Revenue. The Revenue has been decreasing by -13.72% on average per year.
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)-17.7%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.02%
3.2 Future
AKBA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.81% yearly.
The Revenue is expected to grow by 23.71% on average over the next years. This is a very strong growth
EPS Next Y99.23%
EPS Next 2Y58.53%
EPS Next 3Y40.83%
EPS Next 5Y28.81%
Revenue Next Year59.48%
Revenue Next 2Y44.28%
Revenue Next 3Y27.26%
Revenue Next 5Y23.71%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AKBA. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 9.86 indicates a reasonable valuation of AKBA.
Based on the Price/Forward Earnings ratio, AKBA is valued cheaper than 97.74% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, AKBA is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.86 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AKBA is valued cheaply inside the industry as 93.41% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.14 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AKBA's earnings are expected to grow with 40.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.53%
EPS Next 3Y40.83%
5. Dividend
5.1 Amount
No dividends for AKBA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.67
-0.09 (-5.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.13%
Inst Owner Change1.26%
Ins Owners3.57%
Ins Owner Change1.4%
Market Cap442.80M
Revenue(TTM)160.18M
Net Income(TTM)-36.48M
Analysts87.27
Price Target7.55 (352.1%)
Short Float %11.73%
Short Ratio8.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)132.68%
Min EPS beat(2)100%
Max EPS beat(2)165.36%
EPS beat(4)2
Avg EPS beat(4)47%
Min EPS beat(4)-54.81%
Max EPS beat(4)165.36%
EPS beat(8)5
Avg EPS beat(8)38.39%
EPS beat(12)7
Avg EPS beat(12)14.69%
EPS beat(16)8
Avg EPS beat(16)19.03%
Revenue beat(2)2
Avg Revenue beat(2)27.45%
Min Revenue beat(2)25.24%
Max Revenue beat(2)29.66%
Revenue beat(4)3
Avg Revenue beat(4)14.85%
Min Revenue beat(4)-17.55%
Max Revenue beat(4)29.66%
Revenue beat(8)3
Avg Revenue beat(8)0.04%
Revenue beat(12)5
Avg Revenue beat(12)-0.56%
Revenue beat(16)8
Avg Revenue beat(16)11.67%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)37.5%
EPS NQ rev (3m)45.31%
EPS NY rev (1m)88.64%
EPS NY rev (3m)96.09%
Revenue NQ rev (1m)11.86%
Revenue NQ rev (3m)24.87%
Revenue NY rev (1m)6.58%
Revenue NY rev (3m)19.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.86 | ||
| P/S | 2.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 15.15 | ||
| P/tB | N/A | ||
| EV/EBITDA | 22.14 |
EPS(TTM)-0.07
EYN/A
EPS(NY)0.17
Fwd EY10.14%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.77
BVpS0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.56% | ||
| ROE | -124.84% | ||
| ROCE | 1.76% | ||
| ROIC | 1.39% | ||
| ROICexc | 3.52% | ||
| ROICexgc | 10.33% | ||
| OM | 1.96% | ||
| PM (TTM) | N/A | ||
| GM | 83.22% | ||
| FCFM | N/A |
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
F-Score4
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 7.6 | ||
| Cap/Depr | 0.76% | ||
| Cap/Sales | 0.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.84 | ||
| Altman-Z | -4.86 |
F-Score4
WACC7.9%
ROIC/WACC0.18
Cap/Depr(3y)0.13%
Cap/Depr(5y)0.3%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y99.23%
EPS Next 2Y58.53%
EPS Next 3Y40.83%
EPS Next 5Y28.81%
Revenue 1Y (TTM)-17.7%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.02%
Revenue Next Year59.48%
Revenue Next 2Y44.28%
Revenue Next 3Y27.26%
Revenue Next 5Y23.71%
EBIT growth 1Y111.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y92.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.09%
OCF growth 3YN/A
OCF growth 5YN/A
AKEBIA THERAPEUTICS INC / AKBA FAQ
What is the fundamental rating for AKBA stock?
ChartMill assigns a fundamental rating of 3 / 10 to AKBA.
Can you provide the valuation status for AKEBIA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 5 / 10 to AKEBIA THERAPEUTICS INC (AKBA). This can be considered as Fairly Valued.
How profitable is AKEBIA THERAPEUTICS INC (AKBA) stock?
AKEBIA THERAPEUTICS INC (AKBA) has a profitability rating of 4 / 10.
Can you provide the financial health for AKBA stock?
The financial health rating of AKEBIA THERAPEUTICS INC (AKBA) is 1 / 10.